Biotech stocks have continued to be market-leading targets for investors through the coronavirus stock market crash and rebound. Moderna, Inc. (NASDAQ: MRNA), USA Equities Corp. (OTC: USAQ) and Gilead Sciences (NASDAQ: GILD) are getting a lot of attention now.
Moderna, Inc., (NASDAQ: MRNA) a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and autoimmune and cardiovascular diseases. As of February 14, 2020, the company had 12 programs in clinical trials and a total of 24 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation, as well as the Coalition for Epidemic Preparedness Innovations. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
On December 20, 2019 USA Equities Corp (OTC: USAQ) entered into and consummated a share exchange with the former stockholders of Medical Practice Income, Inc. (MPI), a Florida corporation. As a result of the Share Exchange, MPI became our wholly-owned-subsidiary. We are focused on value-based healthcare solutions, clinical informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. The Company’s intellectual properties, products and information service portfolio is directed towards prevention, early detection, management and reversal of cardio-metabolic and other chronic diseases. Our principle objectives are to develop proprietary software tools, devices, and approaches, providing more granular, timely, and specific clinical decision-making information for practicing physicians and other health care providers to address todays obese, diabetic and cardiovascular disease population and is located in West Palm Beach, Florida. For more information, visit www.MedicalPracticeIncome.com/discover.
Now more than ever, technology and machine learning is at the forefront of patient care. Medical Practice Income addresses prevention and reduces such conditions as cardiovascular disease, diabetes, metabolic syndrome, and obesity through its innovative mobile and cloud-based software platforms.
One of the company’s recent launch is QHSLab, a Software as a Service (SaaS) platform today.
The Quality Health Score Lab Expert System (QHSLab) provides physicians and other healthcare organizations an advanced platform to capture patient information and store it in a secure, electronic database. It is then intelligently filtered, analyzed, and processed according to specific algorithms, managing large quantities of data with accuracy and precision.
QHSLab will be brought to the marketplace through approximately 150 primary care practices in Florida. Physicians, nurse practitioners, and ancillary medical practice staff will be active users of this platform, utilizing its proprietary algorithm initially for selecting appropriate allergen immunotherapy treatment sets for their patient populations.
Primary care physicians are overwhelmed by the number of patients suffering from allergies. Allergies often signal other health related concerns, indicating an immune system that is going wrong. Doctors need easy-to-use, digital medicine solutions that save time and money, while delivering the right treatment to patients that need it. Through our AI-enhanced, physician-directed platform, QHSLab, we are increasing the primary care physicians ability to more effectively address the issues with their patients, while saving patients time and expensive visits to a specialist when not absolutely necessary,” said Troy Grogan, President and CEO of Medical Practice Income, Inc.
Gilead Sciences, Inc., (NASDAQ: GILD) a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company’s products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; and Yuhan Corporation. The company was founded in 1987 and is headquartered in Foster City, California.